GSK (GSK) was downgraded by
Weiss Ratings from "buy (b-)" to "hold (c+)".
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows